Figure 3

RBD targeted COVID vaccine and full length spike-protein vaccine (mutation and glycosylation role) relationship with procoagulant effect

Luisetto M*, Tarro G, Farhan Ahmad Khan, Khaled Edbey, Mashori GR, Ahnaf Ilman, Yesvi AR and Latyschev OY

Published: 26 April, 2021 | Volume 5 - Issue 1 | Pages: 001-008

jcavi-aid1007-g003

Figure 3:

SARS-CoV-2, the spike (S) protein and its receptor binding-domain (RBD). (A) Coronaviruses have their name because they are decorated by prominent S proteins (yellow/green). It is the only viral protein that interacts with host cells and is the most diverging protein between different coronaviruses, particularly in its receptor binding-domain (RBD, green). RBD binds to angiotensin converting enzyme 2 (ACE2, not shown) on the host’s cell surface. The fusion peptide (FP) fuses with the host cell membrane. Specific antibodies against RBD and FP can neutralize SARS-CoV-2 NTD/CTD, N-/C-terminal domains. (B) RBD is glycosylated and methylated, which may hinder the induction of neutralizing antibodies. In contrast, the receptor interaction site (RIS, green) is not glycosylated.

Read Full Article HTML DOI: 10.29328/journal.jcavi.1001007 Cite this Article Read Full Article PDF

More Images

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More